Corporate Presentation

June 2023

PeptiDream Inc.

(TSE : 4587)

PeptiDream

PeptiDream - Investment Highlights

Global Leader in the Discovery and Development of Macrocyclic Peptide Therapeutics

Industry Leading Peptide Discovery Platform

PeptiDream's proprietary Peptide Discovery Platform System (PDPS) technology

- Unparalleled peptide library generation (trillions) and hit finding platform
- Unrivaled # of building blocks
- Continuous evolution of the technology, translating learnings from advancing programs back into the platform improvements
- World-class chemistry, biology, bioinformatics, structural biology, modeling, profiling and ADME teams to turn hit peptide candidates into development candidates

Strong IP portfolio

Foundational in Leading and Expanding the Field

PeptiDream at the center of a large and diverse network of discovery and development partnerships

- Collaborations with large, mid, and small sized pharma companies all over the world creating the ecosystem
- Licensing of the PDPS discovery platform to global and Japan pharma partners solidifies the network around a common platform.
- Further grow the network and modality through strategic partnerships
- Develop products in house and license to network partners

PeptiDream

Diverse Big Pharma-Sized Pipeline

PeptiDream has a large diverse pipeline of programs spanning peptide modality, disease areas and development partners

- Over 120+ discovery and development programs
- Spans variety of peptide modalities, from peptide therapeutics to peptide-drug conjugates (PDCs) to multi-functional peptide conjugates (MPCs)
- Across broad range of therapeutic areas and discovery and development partners

Markets 24 radiodiagnostic and 8 radiotherapeutic products in Japan through PDRadiopharma

Business Model Driving Profitability and Growth

PeptiDream's unique multifaceted business model has allowed company to be profitable since 2011

- Year over year growth in revenue and profits from three complementary and synergistic business strategies
- Grow the business and the pipeline through partnerships and cash flow, not through capital raises
- Phenomenal growth potential as the pipeline matures

Japan radiopharmaceutical and radiodiagnostic business provides stable, positive cash flow

PeptiDream – Historical Snapshot

From University Startup to Growing Japan-Based Drug Discovery Powerhouse



PDRadiopharma facility (Chiba)

PeptiDream headquarters (Kawasaki)

PeptiDream Founded
(Spinout from the University of Tokyo)

2006
Revenue/ Total employees

Listed on the TSE Mothers
(Ticker: 4587)

2013
JPY 0.6B / 32 employees

Changed to the first section of the TSE

2015
JPY 2.4B / 50 employees

2017
JPY 4.8B/ 68 employees

Relocated corporate headquarters to Kawasaki

2020
JPY 11.6 B/ 157 employees

Changed to the Prime Market of the TSE

Acquired PDRadiopharma Inc.
(Radiopharmaceutical business)

2022
JPY 26.8 B/ 680 employees

Note: Financial numbers prior to FY2021 are based on JGAAP, IFRS is applied after FY2022.

PeptiDream's Equity Holdings

Wholly-Owned, Affiliated, and Strategic Ownership Stakes in Peptide-Related Companies



Note: (Year) represents the year that PeptiDream invested in the company.

Macrocyclic Peptides as an Expanding Drug Class

Several Approved Macrocyclic Peptide Drugs With Over $1B in Annual Sales

PeptiDream

Long History of Macrocyclic Peptides As Drugs



Blockbuster Macrocyclic Peptides

Drug name	Indication	Peak Sales ($M)
Restasis (cyclosporine)	Chronic dry eye	1,488
Somatuline (lanreotide)	Acromegaly; Neuroendocrine tumors	1,424
Sandostatin (octreotide)	Acromegaly; Symptoms of Carcinoid tumors and VIPomas	1,413
Sandimmune/Neoral (cyclosporine)	Transplant rejection	1,338
Cubicin (daptomycin)	complicated skin and skin structure infections (cSSSI)	1,187

Macrocyclic Peptides Have Positive Features of Both Small & Large Molecules



Small molecules

- Good at recognizing binding pockets but not PPIs or shallow surfaces
- Orally bioavailable
- Membrane permeable
- Near limitless targets
- However difficult and time consuming to find

Macrocyclic peptides



- High affinity and specificity
- Good at inhibiting PPIs
- Good at recognizing shallow interacting surfaces and binding pockets
- Oral bioavailability possible
- Near limitless targets
- Relative ease and speed in finding a suitable hit

Large molecules



- High affinity and specificity
- Good at inhibiting PPIs
- Good at recognizing shallow interacting surfaces of proteins
- Not oral – limited targets
- Relative ease and speed in finding a suitable hit

Most approved macrocyclic drugs arose from natural products, limiting discovery!

Note: 1) Approved by CDER (Center for Drug Evaluation and Research) as new molecular entities.
Source: FDA, Chemistry & Engineering News, Company websites.

PDPS is a Powerful Peptide Discovery Platform

Unparalleled Macrocyclic Peptide Library Generation and Hit Finding Technology

PeptiDream

Amino Acid (AA) Building Blocks



PeptiDream's 3000+ AAs:

- Canonical AAs
- Non-canonical AAs
  - L-AAs w/ novel side chains
  - N-alkyl AAs
  - *D*-AAs
  - β-AAs
  - Peptoid AAs

  etc.

Randomized DNA library



10 positions with 20 building blocks

20^{10} = 10,240,000,000,000 different peptides in a library

Trillions of peptides in each library

- ✓ Robust, cell-free synthesis derived by nature's way of making peptides
- ✓ Each peptide "barcoded" via its mRNA/cDNA tag







Amplify recovered sequences and repeat



Amplify candidate peptides over iterative rounds of selection

Automated PDPS Workstation



Target protein

Peptide binder

High rate of hit finding success

- ✓ Discover high affinity and highly selective macrocyclic peptide binders to almost any target quickly and efficiently
- ✓ Yields unique hit candidates unlike any other technology
- ✓ Technology can be used to optimize and fine-tune the drug-like properties

Continuously evolving platform

- ✓ Continuous expansion of AA building blocks that libraries can be made with and optimized from (grew from 200 to >3,000)
- ✓ Automation of the platform (high throughput)
- ✓ Growing in-silico methods, computer simulation and modeling to predict optimal features
- ✓ Protected by a broad patent portfolio

The Expanding Applications of Macrocyclic Peptides

Turning PDPS Identified Seeds Into a Growing Array of Peptide Therapeutics

PDPS Identified Macrocyclic Peptide Seeds





Key Advantages

- **Affinity and selectivity** comparable to antibodies
- Unique epitopes and **MOAs**
- Differentiating PK & ADME characteristics
- **Oral administration** & other routes possible
- Enable small molecule discovery

- **Peptide ideal at targeting and payload delivery**
- More amenable to a greater array of payloads compared to other modalities.
- Simple robust conjugation chemistry
- Tunable PK/ Differentiating route of elimination

- **RI-PDC: Ideal fit** with radioisotope payloads
- **Oligo-PDC:** Enable **delivery of oligonucleotide/siRNA** drugs to specific tissues/cells
- **Cytotoxic-PDC:** unique beneficial attributes

- Extremely powerful and modular
- Design and generate **multi-functional peptide drugs** by conjugating/linking several peptides with different MOAs together
- Various configurations, such as bifunctional, trifunctional, and more

Expansion of R&D Capabilities

Unlocking Greater Value and Increasing Control

PeptiDream's role in collaborations has increased over time

R&D Capabilities (2010)



R&D Capabilities (2022)



Increasing research capabilities allows for:

- Greater role in partnerships
- More control over program progress
- Larger deal financials
- Ability to take internal programs further before partnering/ out-licensing



Unique Multifaceted Business Model

Business Model Spread Across 4 Strategies

PeptiDream

PeptiDream

Drug Discovery and Development Business Segment

1. **Collaboration Drug Discovery and Development**
2. **PDPS Technology Licensing**
3. **Strategic Alliance/ In-House Program**

Radiopharmaceuticals Business Segment

100% PDRadiopharma

4. **R&D, Manufacturing and Sales of Radiopharmaceuticals/Diagnostics**

Revenue Source		
Short-term	**Mid-term**	**Long-term**
Upfront Research funding Preclinical milestones	Development milestones	Royalties
Licensing and maintenance fees	Development milestones	Royalties
	Out-licensing fee, development milestones	Royalties
Product Sales (Existing products)	Product Sales (In-licensed products)	Product Sales (PeptiDream products)

1 Collaboration Drug Discovery and Development

Combining PeptiDream's Expertise With Big Pharma's Drug Development Know-How and Capabilities

- **Lead & Expand:** Leadership position in the space – drive expansion of macrocyclic peptide ecosystem
- **More Programs:** Allows PeptiDream to work on a larger number of programs with less staff/resources than otherwise possible
- **Build Expertise:** Continuously build in-house expertise by working with and learning from big pharma
- **Diversify Risk:** Diversify business risk with a broad portfolio of programs and partners (success not tied to any one program or partner)

5-Year Snapshot



Note: Merck & Co., Inc., Rahway, NJ, USA.

2 PDPS Technology Transfer/Licensing

Transfer and Establish Operation of PDPS Technology Within Partner Companies

- **Platform Validation:** Non-exclusively licensed PDPS technology to 11 companies
- **Establish as Standard:** Make PDPS technology the global standard to discover macrocyclic peptides
- **Grow People:** Partners expand staff, resources, capabilities around PDPS and peptide discovery and development
- **Licensing Revenue:** PeptiDream receives licensing revenue along with downstream milestones/royalties on any products
- **Carveout PDCs:** PDPS technology licenses included PDC carveout, partners must work with PeptiDream to do PDCs



Note: Merck & Co., Inc., Rahway, NJ, USA.

3 In-House/Strategic Discovery and Development

Growing and Accelerating In-house Discovered Programs Through Strategic Partnerships

- **Access expertise/technology:** Access to expertise and/or technology/know-how PeptiDream does not possess
- **Increased Speed/Control:** Streamlined focus and decision making, defined roles, greater control = program acceleration
- **Greater Upside:** Faster and greater monetization of programs at lower cost/risk

In-House Programs

Develop internally and out-license to third party for clinical development

Jan 2018

- Started internal program to develop GhR antagonists

Dec 2020

- Formed strategic partnership with licensing option

Sep 2021

- Amolyt exercised license option, initiated IND enabling studies, entering clinic in 2023

Strategic Partnership

Joint - Development and out-license to third party for clinical development

Feb 2016

- Started research collaboration

May 2019

- Successfully identified TfR binding peptides that could deliver to muscle and CNS

Dec 2020

- Exclusive research and license deal to peptide-oligo PDCs for neuromuscular diseases

Jul 2021

- Extended deal to certain CNS targets

Preclinical Collaboration

Joint – Development and partner takes over clinical development

Jul 2017

- Started research collaboration with Biohaven

Jun 2019

- Identified CD38-ARM™ as clinical candidate

Feb 2020

- IND authorization obtained for CD38-ARM™

Sep 2020

- Orphan Drug Designation by FDA to CD38-ARM™

Oct 2021

- Phase1a/1b started for CD38-ARM™

4 Global Radiopharmaceutical Market

Experiencing Significant Growth From Targeted Radiotherapeutics/Diagnostics

- **Targeted radiotherapy:** Lutathera and Pluvicto demonstrating high efficacy – driving further investment/products in the space

Market Growth

Worldwide



Japan

Larger growth in RI therapeutics is expected in Japan market



Major Players

- Novartis/AAA
- Bayer
- Lantheus
- Curium
- ITM
- Eli Lilly/Avid
- Point Biopharma
- RayzeBio
- PDRadiopharma
- Nihon Mediphysics

Clinical Pipeline and Marketed Radiotherapeutics[2)]

Company	SSTR	PSMA	FAP	HER2	NTSR1	GRPR	CAIX	CD45	B7H3	CD33	CD66	LAT1	FGFR3	GIPR	IGFR1	Integrin αvβ3/5	PARP
Novartis	■	■	■			■										■	
Telix Pharmaceuticals		■					■				■	■					
3B Pharmaceuticals			■		■		■							■			
Point Biopharma	■	■	■														
Clarity Pharmaceuticals	■	■				■											
Fusion Pharma					■								■		■		
Lantheus	■	■															
Actinium Pharmaceuticals								■		■							
ITM	■	■															
Precirix			■	■													
Bayer		■		■													
Full-Life/ Focus X		■			■												
NanoMab			■	■													
RadioMedix	■	■															
Curium		■															
RayzeBio	■																
Y-mAbs Therapeutics									■								
Ariceum Therapeutics	■																
Andarix	■																
Theragnostics																	■

■ = Marketed ■ = Clinical stage ■ = Preclinical stage

Note: 1) Estimate from the data of JRIA, Exchange rate JPY/USD=140; 2) Partnered programs may be counted twice (e.g., Fusion and 3B, Point and Lantheus).
Source: 1) JRIA, Global information, Analysis of BofA 2) Company websites as of end of January 2023

4 PD/PDR Ideally Positioned to be a Major Player

Leveraging PD's Radiotherapeutic Discovery Role With PDR's Unique Japan Market Presence

Key Features of the Radiopharmaceutical Market in Japan

- Only 2 licensed radiopharmaceutical companies in Japan due to highly regulated market
- High barrier to Japan market entry, strict regulations and supply chain requirements to handle radiopharmaceuticals
- Partnering with a local Japanese company is essential for global pharma companies to commercialize their radiopharmaceutical products in Japan

PeptiDream

- Already playing a leading global role in the discovery and development of target radiotherapies (peptide-RI conjugates) through partnerships with Novartis, RayzeBio and Bayer
- Growing pre-clinical pipeline of peptide-RI conjugates
- Strong global reputation and connections with big pharma and the other major radiopharmacuetical players

⊕

PDRadiopharma

- Founded in 1968: experts with deep experience in radiopharmaceuticals
- Long relationships with regulators, KOLs, radiologists/hospitals
- Vertically integrated infrastructure with R&D, manufacturing and commercialization capabilities in Japan
- 8 therapeutic and 24 diagnostic products on the market
- Network of global radioisotope suppliers and vendors

Combining with PDRadiopharma enables PeptiDream to both accelerate and maximize the value of the peptide-RI products it is discovering and developing

PD/PDR Radiopharmaceutical Product Offerings

3 Strategies to Grow PD/PDR Product Portfolio and Revenue



PeptiDream Pipeline Snapshot

Consistent Year-Over-Year Advancement of Programs Through Preclinical Into Clinical Development

Number of programs per stage



Recent Highlights:

Bristol Myers Squibb	**PD-L1 inhibitor**	**Oncology**	• Partnered with BMS • Initiated Phase 1 in April 2022 • Blockbuster potential
Biohaven	**CD38-ARM™**	**Multiple myeloma**	• Partnered with Biohaven • Received FDA orphan drug designation in 2020 • Initiated Phase 1a/1b in October 2021
AMOLYT PHARMA	**AZP-3813**	**Acromegaly, Others**	• Licensed to Amolyt • Addresses inefficiencies in current treatments (currently a $6B market) • Slated to enter Phase 1 in 2023
RayzeBio	**RI-PDC**	**Oncology**	• Partnered with RayzeBio • Nominated the first development candidate arising from the strategic partnership • Nominated the second development candidate against Glypican-3 • Conjugation of radioisotopes and novel peptide binders discovered using PDPS

Note: Numbers do not include programs at PDRadiopharma.

Clinical/Late-Research Stage Pipeline of PeptiDream

Program	Indication	Partner	Preclinical	Clinical (Ph1 / Ph2 / Ph3)	Status
PD-L1 Therapeutic Peptide	Oncology	Bristol Myers Squibb			Phase 1 started April 2022 (ISRCTN17572332)
PD-L1 BMS-986229 RI-PDC (PET diagnostic)	Oncology	Bristol Myers Squibb			Phase 1 started Nov 2019 (NCT04161781)
CD38 BHV-1100 + NK Cells Therapeutic MPC	Multiple Myeloma	Biohaven			Phase 1a/1b started Oct 2021 (NCT04634435)
S2-protein PA-001 Therapeutic Peptide	COVID-19	PeptiAID			Clinical research completed (jRCTs031210601); Planning next development steps
GhR AZP-3813 Therapeutic Peptide	Acromegaly/NET	AMOLYT PHARMA			Currently in IND enabling studies / Entering clinic in 2023
Glypican-3 RI-PDC	Liver cancer	RayzeBio			Selected clinical development candidate (Mar. 2023)/ GLP-Tox to IND stage
Myostatin Therapeutic Peptide	DMD/ Muscle Disorders	In-house (Kawasaki Med. School)			Selecting clinical development candidate / Considering partnering options
Undisclosed RI-PDC	Oncology	RayzeBio			Selected clinical development candidate (Dec. 2022)/ GLP-Tox to IND stage
Undisclosed RI-PDC	Oncology	NOVARTIS			Lead to GLP-Tox stage
TfR Oligo-PDC	Neuromuscular Disorders	Takeda			Lead to GLP-Tox stage
c-Kit Therapeutic Small Molecule	Allergic Condition	MODULUS			Partnering discussions
c-Met Therapeutic Peptide	Undisclosed	Genentech A Member of the Roche Group			Lead to GLP-Tox stage
HA-protein PD-001 Therapeutic Peptide	Influenza	In-house			Considering partnering options in light of changing global market environment

PDRadiopharma Product Portfolio

8 Therapeutic and 24 Diagnostic Products on the Market

PeptiDream

- Promote use and indication expansion of existing approved products

	Product/Program Target	Radio-isotope	Indication	Partner	Preclinical	Clinical			Marketed
						Ph1	Ph2	Ph3	
Tx	Sodium Iodide Capsule	^{131}I	Hyperthyroidism/Primary and Metastatic Thyroid Cancer	In-house					
Tx	Raiatt MIBG	^{131}I	MIBG avid Pheochromocytoma/ Paraganglioma	In-house					
Tx	Zevalin® CD20	^{90}Y	Low-grade non-Hodgkin's B-cell Lymphoma/Mantle Cell Lymphoma	Mundipharma					
Dx	OctreoScan® SSTR	^{111}In	Somatostatin Receptor Scintigraphy	Curium					
Dx	Techne® MDP	^{99m}Tc	Bone Scintigraphy	In-house					
Dx	Neurolite®	^{99m}Tc	Cerebral Blood Flow	Lantheus Medical Imaging					
Dx	Cardiolite®	^{99m}Tc	Heart Disease/ Hyperparathyroidism	Lantheus Medical Imaging					
Dx	MyoMIBG®	^{123}I	Heart Disease/ Pheochromocytoma/ Neuroblastoma	In-house					
Dx	Tl201	^{201}Tl	Heart Disease	In-house					
Dx	Ultra-Techne Kow®	^{99m}Tc	Brain Diseases/Thyroid Disease/Salivary Gland Disease	In-house					
Dx	Amyvid® β-Amyloid	^{18}F	Visualization of amyloid beta plaques for patients with suspected AD dementia	Eli Lilly/ Avid Radiopharmaceuticals					
Dx	FDG	^{18}F	Malignant Tumor/ Heart Disease/ Intractable Partial Epilepsy/ Large-vessel Vasculitis	In-house					

Note: Tx: Therapeutics, Dx: Diagnostics; FDG = Fluorodeoxyglucose; As of end of Nov 2022.

Clinical Pipeline of PDRadiopharma

New Co-Development Deal With Eli Lilly for Tauvid® Signed in 2022

- 4 clinical-stage programs currently in development
- Planning to further expand PDRadiopharma's pipeline and product portfolio in the future
  - In-license assets already approved or in late-stage development overseas / service agreements to develop/commercialize in Japan
  - Develop PeptiDream's in-house and partnered development programs in Japan

	Program/ Target	Radioisotope	Indication	Clinical Ph1	Clinical Ph2	Clinical Ph3	Marketed	Notes
Dx	Tauvid® Tau	^{18}F	Alzheimer's disease	Co-development with Eli Lilly in Japan			US (Eli Lilly)	Approved by US FDA in 2020
Dx	F-1311 PSMA	^{99m}Tc	Prostate cancer	Japan (PDR)			US (Lantheus)	In-licensed from Lantheus Medical Imaging
Thx	FF-10158 Integrin αvβ3/5	^{68}Ga/ ^{177}Lu	Malignant glioma and others	US/ EU (NVS)				Out-licensed ex-Japan rights to Novartis PDR retains Japan rights
Thx	PPMX-T002 Cadherin3	-	Advanced and recurrent solid tumors	Japan (PPMX)	US (PPMX)			Co-owned with Perseus Proteomics (PPMX) PPMX leading out-licensing activities

Note: Dx: Diagnostics, Thx: Theranostics; As of Dec 2022.

PeptiDream Financial Performances and Near-term Catalysts

Year-Over-Year Revenue and Profit Growth

Financial performance

- Consistent revenue and profit growth
- Reinvesting profits to further grow the business and pipeline
- Acquisition of PDRadiopharma adds cash flow/revenue
- Goal of JPY100B in revenue by 2030



Market Capitalization[1)] (As of May 31, 2023)	JPY 279.6 B

Future catalysts

- **Progress of On-going Clinical Programs**
  - Next-Generation PD-L1 Inhibitor: Ph1 results/entry into Ph2
  - CD38-ARM: Ph1a/1b clinical results
  - PA-001: Development progress/out-licensing
- **Initiation of New Clinical Programs**
  - AZP-3813: Entry into Ph1 in 1H 2023
  - Myostatin Inhibitor: Selection of development candidate/considering out-licensing/development options
  - RI-PDC Program (RayzeBio): Advancing 1st/ 2nd development candidate
  - RI-PDC Program (Novartis, in-house): Selection of development candidate
  - Oligo-PDC Program ： Selection of development candidate
- **New Deals for Research Collaboration/ PDPS Licensing**
  - Expansion of PDC programs / PDPS Licensing
  - MPC programs – asset creation/potential deals
- **Others**
  - Partnering for KIT selective inhibitor

Note: From FY2019, fiscal year end changed from changed from June 30 to December 31. The financial performance between 2019/7 and 2019/12 (6 months) are excluded from this figure.
1) Yahoo! Finance.

References

Leadership Team at PeptiDream

Representative Director, President, CEO

Patrick C. Reid, Ph.D.

- Co-founder of PeptiDream, after working as Associate Professor at University of Tokyo
- CSO, Head of R&D until 2017
- CEO at PeptiDream 2017 to current
- Ph.D. in Biochemistry from Dartmouth Medical School

Director, COO

Keiichi Masuya, Ph.D.

- Joined PeptiDream in Jul 2014, previously Head of PPI Drug Discovery at Novartis International AG
- Director of PDRadiopharma, Director at PeptiGrowth, Representative Director and President at PeptiAID
- Ph.D. in Chemistry from Tokyo Institute of Technology

Director, CFO

Kiyofumi Kaneshiro, Ph.D.

- Joined PeptiDream in Jan 2018, previously Partner and Managing Director at the Boston Consulting Group
- Director of PDRadiopharma, Director at PeptiAID
- Ph.D. in Oncology from University of Tokyo

Chief Medical Officer

Masato Murakami, M.D., Ph.D., MBA

- Joined PeptiDream in Jan 2022, previously Vice President of the Global Precision Medicine Department at Daiichi-Sankyo
- M.D. from Tokai University School of Medicine (trained pathologist)
- Ph.D. in Medicine from University of Tokyo

Head of Business Development

Yen Ting Chen, Ph.D.

- Joined PeptiDream in May 2022, previously Vice President at Locust Walk Japan
- Ph.D. in Chemistry from Brown University

Head of IR & Public Affairs

Yuko Okimoto, Ph.D.

- Joined PeptiDream in May 2020, previously Director at Global Investment Banking Division of Mizuho Securities
- Ph.D. in Chemistry from University of Tokyo

External Directors at PeptiDream

Independent External Director
(Auditing Committee Member)
Michio Sasaoka, Ph.D.

- Joined PeptiDream in May 2012, after working at Massachusetts Institute of Technology as Postdoctoral Research Associate, Otsuka Chemical Co., Ltd. as Director of Explorative Laboratory
- Currently Independent Outside Director (Auditing Committee Member) at PeptiDream

Independent External Director
(Auditing Committee Member)
Junko Utsunomiya (Attorney)

- Joined PeptiDream in Mar 2021, after working at Nagashima Ohno & Tsunematsu, Utsunomiya Shimizu & Haruki Management Legal Office as a founding partner
- Currently Independent Outside Director (Auditing Committee Member) at PeptiDream

Independent External Director
(Auditing Committee Member)
Toshio Nagae

- Joined PeptiDream in Sep 2015, after working at Shionogi & Co., Ltd., Sanofi K.K. as Executive Officer of Aventis Pharma, York Pharma K.K as President and Representative Director
- Currently Independent Outside Director (Auditing Committee Member) at PeptiDream

Independent External Director
(Auditing Committee Member)
Yukinori Hanafusa (Certified Public Accountant)

- Joined PeptiDream in Mar 2016, after working at Aoyama Audit Corporation, Accounting Works Co., Ltd. as Founding Representative Director, ARCLAND SERVICE HOLDINGS CO., LTD as Director
- Currently Independent Outside Director (Auditing Committee Member) at PeptiDream

Forward-Looking Statements

This presentation contains forward-looking statements. These forward-looking statements are current plans, forecasts, assumptions and strategies based on currently available information. There are various inherent risks as well as uncertainties involved. The actual results of business performance may differ from those forecasts due to various factors.

These factors include, but are not limited to: (1) risks of delays, interruptions or failures associated with drug discovery and development; (2) risks of unexpected program disruptions or terminations due to changes in client policies; (3) risks associated with manufacturing products and the procurement of raw materials; (4) the impact of reduced competitiveness due to the competitors and competing technologies; (5) declining product sales capabilities; (6) adverse rulings in infringements or significant litigation against our Group's intellectual property rights; (7) adverse changes in economic conditions and related laws and regulations; and (8) fluctuations in interest rates and currency exchange rates.

The information in this material with respect to drugs (including those under development) is not intended to provide advertising or medical advice.

This material is intended to provide information on our Group's business and is not intended to solicit investment in securities.

PeptiDream assumes no responsibility for any damages resulting from the use of this material or its content, including without limitation damages related to the use of erroneous information.